Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

Delayed Quote. Delayed  - 09/30 10:05:02 pm
53.92 USD   +0.09%
09/28 GLOBAL DRUGS FO : Janssen, Celgene, Bristol-Myers Squibb, Grunenthal..
09/28 RAYTHEON : Adds Harman CEO Dinesh Paliwal to Board of Directors
09/27 BRISTOL MYERS S : and Nektar Therapeutics Announce Oncology Clinical..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
09/26/2016 09/27/2016 09/28/2016 09/29/2016 09/30/2016 Date
55.48(c) 55.74(c) 55.09(c) 53.87(c) 53.92(c) Last
8 599 822 8 619 892 13 768 416 17 228 510 12 060 055 Volume
-1.77% +0.47% -1.17% -2.21% +0.09% Change
More quotes
Financials ($)
Sales 2016 18 872 M
EBIT 2016 4 999 M
Net income 2016 4 369 M
Debt 2016 1 166 M
Yield 2016 2,87%
Sales 2017 20 284 M
EBIT 2017 5 766 M
Net income 2017 5 069 M
Finance 2017 1 089 M
Yield 2017 3,03%
P/E ratio 2016 20,85
P/E ratio 2017 18,04
EV / Sales2016 4,84x
EV / Sales2017 4,39x
Capitalization 90 093 M
More Financials
Company
Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products.Its pharmaceutical products include chemically-synthesized drugs or small molecules and an increasing portion of products produced from... 
Sector
Pharmaceuticals
Calendar
10/05Ex-dividend day
More about the company
Surperformance© ratings of Bristol-Myers Squibb Co
Trading Rating : Investor Rating :
More Ratings
Latest news on BRISTOL-MYERS SQUIBB CO
09/29 BRISTOL MYERS SQUIBB : to Take Part in Leerink Partners Immuno-Oncology Roundtab..
09/29 BRISTOL MYERS SQUIBB : European Medicines Agency Validates Bristol-Myers Squibb'..
09/29 BRISTOL MYERS SQUIBB : Study Data from Bristol-Myers Squibb Update Understanding..
09/29 BRISTOL MYERS SQUIBB : Researchers at Bristol-Myers Squibb Target Pharmaceutical..
09/29 BRISTOL MYERS SQUIBB : Awards First "Golden Tickets" for LabCentral to PanTher, ..
09/29 BRISTOL MYERS SQUIBB : New Hepatitis C Virus Study Findings Reported from Bristo..
09/29 BRISTOL MYERS SQUIBB : New Findings from Bristol-Myers Squibb Update Understandi..
09/29 BRISTOL MYERS SQUIBB : New Findings in Immunoglobulins Described from Bristol-My..
09/29 BRISTOL MYERS SQUIBB : Data from Bristol-Myers Squibb Provide New Insights into ..
09/29 BRISTOL MYERS SQUIBB : Findings from Bristol-Myers Squibb in the Area of Molecul..
More news
Sector news : Pharmaceuticals - NEC
09/30DJGLAXOSMITHKLINE : to Pay $20 Million to Settle SEC Bribery Probe
09/30 GlaxoSmithKline to pay $20 million to settle U.S. foreign bribery case
09/30DJGLAXOSMITHKLINE : to Pay $20 Million to Settle SEC Bribery Probe
09/30DJSHIRE : Files 8K - Other Events
09/30DJNovo Nordisk Announces Job Cuts
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on BRISTOL-MYERS SQUIBB CO 
09/26Attractive price levels
More Strategies
News from SeekingAlpha
09/29 Bristol-Myers Squibb (BMY) Presents at Leerink Partners Rare Disease & Immuno..
09/29 Novel Checkpoints Add To The Parp Showdown
09/28 BEST NEAR-TERM PRICE GAINS AHEAD FOR : Big Pharma Stocks
09/28 Market Is Rewarding High Growth Stocks - Cramer's Mad Money (9/27/16)
09/27 Bristol-Myers and Nektar Therapeutics to explore potential of Opdivo and NKTR..
Advertisement
Chart BRISTOL-MYERS SQUIBB CO
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 67,4 $
Spread / Average Target 25%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Giovanni Caforio Chief Executive Officer & Director
Lamberto Andreotti Chairman
Charles A. Bancroft Chief Financial Officer & Executive Vice President
Francis M. Cuss Chief Scientific Officer & Executive VP
Paul von Autenried Chief Information Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB C..-21.62%90 093
JOHNSON & JOHNSON15.00%323 189
ROCHE HOLDING LTD.-12.52%214 851
NOVARTIS AG-11.00%207 776
PFIZER INC.4.93%205 444
MERCK & CO., INC.18.16%172 577
More Results